retatrutide clinical trial results Eli Lilly's Phase 3 Results: 28.7% Weight Loss | Drug Discovery & Development posted on the topic Retatrutide (Eli Lilly's triple GLP-1/GIP/Glucagon
Description
The Hidden Threat: Muscle Loss with GLP-1 Medications While GLP-1 receptor agonists are a game-changer for fat loss, they come with a critical downside: muscle loss
The most common side effects are gastrointestinal including nausea, vomiting, and diarrhoea particularly during dose escalation
Or Schedule an introductory call
How Long Do Peptide Stacks Take to Work
Similarly, bariatric surgery often results in a prolonged period of weight loss whereas diet interventions typically exhibit plateaus within 612 months
November 13, 2023
